The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall ...

The FDA said it has identified 76 cases of drug-induced liver injuries with reasonable evidence of being causally linked to ...

Zai Lab and Amgen will collaborate on a clinical trial to evaluate a Zai Lab lung cancer therapy. Under the agreement, Amgen will sponsor a global phase 1b study to evaluate the safety and efficacy of ...

Amgen’s rare disease drug Tavneos is under mounting regulatory scrutiny, with the FDA warning of serious liver injuries, ...

By Puyaan Singh March 31 (Reuters) - The U.S. Food and Drug Administration on Tuesday said it has identified cases of liver ...

A plaza view of Amgen Inc.'s new South San Francisco research and office site in Biomed Realty's Gateway of Pacific complex ...

The FDA has ramped up the pressure on Amgen to withdraw Tavneos for a rare vasculitis condition from the market, with a ...

Biopharma company Amgen plans to add 370 jobs as part of a new, $1.02 billion investment in Holly Springs. It’s the latest move by the company to expand manufacturing capacity in the fast-growing ...

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit ...

AMGN, T, and Roche shares outperform as strong drug portfolios and wireless momentum offset key headwinds like pricing pressure and legacy declines.

Roche's strong drug growth is offsetting legacy declines, while strategic deals aim to reshape its portfolio amid biosimilar pressure and FX headwinds.

Roughly a year and a half after the introduction of a shareholder lawsuit, Amgen has lost its bid to toss the case accusing the California biotech giant of concealing a massive tax bill with the IRS.